|
|
ACM-CPG |
|
Vaxjo ID |
145 |
|
Vaccine Adjuvant Name |
ACM-CPG |
|
Adjuvant VO ID |
VO_0006106
|
|
Description |
An emulsion vaccine adjuvant that targets on TLR-agonist. It is a nucleic acid-based adjuvant for chemical nature |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
Australia |
|
Host Species for Testing |
Human |
|
Second Host Species for Testing |
Mouse |
|
Components |
amphiphilic block copolymer comprising poly(butadiene)-b-poly(ethylene glycol) and a cationic lipid, 1,2-dioleoyl-3-trimethylammonium-propane |
|
Storage |
ACM-CpG adjuvant is stored as liquid formulation at 2-8 °Celsius, avoid freeze-thawing |
|
Function |
Innate Immune Activation, preferential uptake by APCs |
| References |
|
|
